IL129824A - Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants - Google Patents

Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants

Info

Publication number
IL129824A
IL129824A IL12982497A IL12982497A IL129824A IL 129824 A IL129824 A IL 129824A IL 12982497 A IL12982497 A IL 12982497A IL 12982497 A IL12982497 A IL 12982497A IL 129824 A IL129824 A IL 129824A
Authority
IL
Israel
Prior art keywords
xenotransplants
recipient
organ
amino
preventing
Prior art date
Application number
IL12982497A
Other languages
English (en)
Other versions
IL129824A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to IL14709997A priority Critical patent/IL147099A0/xx
Publication of IL129824A0 publication Critical patent/IL129824A0/xx
Publication of IL129824A publication Critical patent/IL129824A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Light Receiving Elements (AREA)
IL12982497A 1996-11-19 1997-11-17 Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants IL129824A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL14709997A IL147099A0 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds
PCT/EP1997/006408 WO1998022100A2 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives

Publications (2)

Publication Number Publication Date
IL129824A0 IL129824A0 (en) 2000-02-29
IL129824A true IL129824A (en) 2003-07-31

Family

ID=10803173

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12982497A IL129824A (en) 1996-11-19 1997-11-17 Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants

Country Status (25)

Country Link
US (3) US6274629B1 (ja)
EP (2) EP1312359B1 (ja)
JP (2) JP4004070B2 (ja)
CN (2) CN1293876C (ja)
AT (2) ATE369846T1 (ja)
AU (1) AU728420B2 (ja)
BR (1) BR9713105A (ja)
CA (1) CA2270952C (ja)
CZ (1) CZ174999A3 (ja)
DE (2) DE69738033T2 (ja)
DK (1) DK1312359T3 (ja)
ES (2) ES2227726T3 (ja)
GB (1) GB9624038D0 (ja)
HK (1) HK1022639A1 (ja)
HU (1) HUP0000343A3 (ja)
ID (1) ID21568A (ja)
IL (1) IL129824A (ja)
NO (1) NO992259L (ja)
NZ (1) NZ335629A (ja)
PL (1) PL190348B1 (ja)
PT (2) PT1312359E (ja)
RU (1) RU2217136C2 (ja)
SI (1) SI1312359T1 (ja)
SK (1) SK284806B6 (ja)
WO (1) WO1998022100A2 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129066B1 (en) 1998-11-11 2005-02-02 Novartis AG Production of 2-amino-2- 2-(4-c 2-20?-alkyl-phenyl)ethyl]propane-1,3-diols
IL149792A0 (en) * 1999-12-16 2002-11-10 Teva Pharma Novel processes for making and a new crystalline form of leflunomide
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
EP1368015B1 (en) * 2001-02-22 2006-08-09 Novartis AG Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
EP1379547B1 (fr) * 2001-04-20 2005-12-21 Debiopharm S.A. Cyclosporine modifiee utilisable en tant que pro-drogue et son utilisation
BR0209319A (pt) * 2001-06-08 2004-07-20 Novartis Ag Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
BR0306811A (pt) 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
EP2769713A1 (en) 2003-04-08 2014-08-27 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
JP2007523858A (ja) * 2003-06-24 2007-08-23 ユニバーシティ オブ コネチカット 血管透過性およびアポトーシスの阻害方法
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
WO2005079788A1 (ja) 2004-02-24 2005-09-01 Sankyo Company, Limited アミノアルコール化合物
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
US8809304B2 (en) 2005-12-15 2014-08-19 Mitsubishi Tanabe Pharma Corporation Amine compound and use thereof for medical purposes
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
ES2964891T3 (es) * 2013-03-05 2024-04-10 Biocon Ltd Un proceso para la preparación de compuestos de 2-amino-1,3-propanodiol y sales de los mismos
EA201890477A1 (ru) 2015-09-18 2018-08-31 Сановел Иладж Санайи Ве Тиджарет А.С. Инкапсулированная композиция финголимода
CN115477590B (zh) * 2021-05-31 2023-12-12 上海云晟研新生物科技有限公司 芬戈莫德药用盐、制备方法、含其的药物组合物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
WO1993002108A1 (en) * 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE122011100012I1 (de) * 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
CA2213989C (en) 1995-12-28 2007-05-29 Yoshitomi Pharmaceutical Industries Ltd. External preparation for topical administration
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
EP0990440B1 (en) * 1997-02-27 2008-10-29 Novartis AG Pharmaceutical composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharide

Also Published As

Publication number Publication date
EP1312359A2 (en) 2003-05-21
JP2001503780A (ja) 2001-03-21
DE69738033D1 (de) 2007-09-27
BR9713105A (pt) 2000-04-11
SI1312359T1 (sl) 2008-08-31
GB9624038D0 (en) 1997-01-08
JP4004070B2 (ja) 2007-11-07
CA2270952C (en) 2007-09-18
ID21568A (id) 1999-06-24
CA2270952A1 (en) 1998-05-28
CN1237906A (zh) 1999-12-08
DK1312359T3 (da) 2007-10-08
HUP0000343A3 (en) 2001-06-28
US6274629B1 (en) 2001-08-14
US20030069315A1 (en) 2003-04-10
AU5483198A (en) 1998-06-10
CN1293876C (zh) 2007-01-10
WO1998022100A2 (en) 1998-05-28
US20010056124A1 (en) 2001-12-27
CN1146411C (zh) 2004-04-21
EP1312359A3 (en) 2004-01-02
DE69738033T2 (de) 2008-04-30
ATE369846T1 (de) 2007-09-15
ATE275947T1 (de) 2004-10-15
HK1022639A1 (en) 2000-08-18
PT1312359E (pt) 2007-11-09
CN1515253A (zh) 2004-07-28
AU728420B2 (en) 2001-01-11
PL190348B1 (pl) 2005-11-30
DE69730727D1 (de) 2004-10-21
JP2004256554A (ja) 2004-09-16
ES2289041T3 (es) 2008-02-01
DE69730727T2 (de) 2005-09-22
PL333463A1 (en) 1999-12-20
IL129824A0 (en) 2000-02-29
SK65999A3 (en) 1999-12-10
US6486209B2 (en) 2002-11-26
ES2227726T3 (es) 2005-04-01
EP1312359B1 (en) 2007-08-15
HUP0000343A2 (hu) 2000-12-28
PT941082E (pt) 2004-12-31
CZ174999A3 (cs) 1999-08-11
SK284806B6 (sk) 2005-11-03
NO992259D0 (no) 1999-05-10
WO1998022100A3 (en) 1998-06-25
EP0941082B1 (en) 2004-09-15
NZ335629A (en) 2001-09-28
NO992259L (no) 1999-05-10
RU2217136C2 (ru) 2003-11-27
EP0941082A2 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
IL129824A (en) Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants
ATE232531T1 (de) Heterobizyklische derivate
DE69415445D1 (de) Zytotoxische Stilben-Derivate und diese enthaltende pharmazeutische Zusammensetzungen
MY136674A (en) Novel quinuclidine carbamate derivatives and medicinal compositions containing the same
ZA9110166B (en) 1,4-benzothiazepine derivatives
KR900016098A (ko) 카페인산의 유도체 및 이를 함유하는 약제학적 조성물
NZ230503A (en) Substituted beta-diketones and pharmaceutical compositions
ATE115572T1 (de) N-2-chlorbenzyl-2-oxo- und n-2-chlorbenzyl-2,2,- dioxo-1,2,3-oxathiazolidinderivate, ihre herstellung und ihre verwendung in der synthese von thieno(3,2-c>pyridinderivaten.
ES2059685T3 (es) Acilaminoalquilpiridinamidas inhibidoras de metastasis tumoral.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees